Roche moved to enter the booming weight-loss drug market now dominated by Novo Nordisk and Eli Lilly. The Swiss ...
Over the past few days, as the rest of the stock market melted down, a revolution has been quietly brewing in the market for ...
Roche agreed to develop a weight-loss drug with Danish biotech Zealand Pharma, pressuring Novo Nordisk and Eli Lilly.
Novo Nordisk on Monday revealed weaker-than-expected data from a second late-stage trial of its obesity drug candidate ...
Novo’s share price fell 8 per cent on Monday, having previously dived in December after a late-stage trial of CagriSema in ...
New trial data showed the drug helped obese or overweight type 2 diabetics lose an average 15.7% of their weight, when an ...
Novo Nordisk stock tumbled Monday morning after disappointing trial results for its CagriSema weight-loss drug. Shares in ...
Novo Nordisk on Monday revealed weaker-than-expected data from a second late-stage trial of its obesity drug candidate ...
Novo Nordisk on Monday revealed weaker-than-expected data from a second late-stage trial of its obesity drug candidate ...
Roche Holding AG hired a senior executive from rival Novo Nordisk A/S as the Swiss drugmaker prepares to enter the ...
Makers of the popular obesity treatments Wegovy and Zepbound are cutting prices for people without insurance. Danish ...
Professor Arne Astrup is also involved in project to change widely-accepted definition of ultra-processed food ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results